Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Merck KGaA (OTCMKTS:MKKGY – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.
Valuation and Earnings
This table compares Sunshine Biopharma and Merck KGaA”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $35.35 million | 0.02 | -$5.97 million | ($170.20) | -0.02 |
| Merck KGaA | $23.87 billion | 0.89 | $2.95 billion | $1.37 | 24.07 |
Merck KGaA has higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Merck KGaA, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Sunshine Biopharma and Merck KGaA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -18.89% | -26.55% | -21.30% |
| Merck KGaA | 8.95% | 6.53% | 3.68% |
Volatility & Risk
Sunshine Biopharma has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Sunshine Biopharma and Merck KGaA, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 0 | 0 | 1.50 |
| Merck KGaA | 0 | 6 | 0 | 0 | 2.00 |
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 0.1% of Merck KGaA shares are owned by institutional investors. 0.4% of Sunshine Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Merck KGaA beats Sunshine Biopharma on 9 of the 12 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
